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Abstract
Down syndrome (DS) has been proposed by George Martin as a segmental proger-
oid syndrome since 1978. In fact, DS persons suffer from several age‐associated dis-
orders much earlier than euploid persons. Furthermore, a series of recent studies
have found that DS persons display elevated levels of age biomarkers, thus support-
ing the notion that DS is a progeroid trait. Nowadays, due to the progressive
advancements in social inclusion processes and medical assistance, DS persons live
much longer than in the past; therefore, the early‐onset health problems of these
persons are becoming an urgent and largely unmet social and medical burden. In
particular, the most important ailment of DS persons is the accelerated cognitive
decline that starts when they reach about 40 years of age. This decline can be at
least in part counteracted by multi‐systemic approaches including early‐onset cogni-
tive training, physical activity, and psychosocial assistance. However, no pharmaco-
logical treatment is approved to counteract this decline. According to the most
advanced conceptualization of Geroscience, tackling the molecular mechanisms
underpinning the aging process should be a smart/feasible strategy to combat and/or
delay the great majority of age‐related diseases, including cognitive decline. We
think that a debate is needed urgently on if (and how) this strategy could be inte-
grated in protocols to face DS‐associated dementia and overall unhealthy aging. In
particular we propose that, on the basis of data obtained in different clinical set-
tings, metformin is a promising candidate that could be exploited to counteract cog-
nitive decline in DS.
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1 | INTRODUCTION
Down syndrome (DS) (OMIM #190685) is a genetic disorder caused
by a partial or complete trisomy of chromosome 21. It is the most
common genetic cause of intellectual disability, which is typically
associated with well‐defined phenotypic characteristics including dis-
tinctive facial features and major congenital malformations.
Life expectancy of DS persons has dramatically increased from
12 years in 1949 to 60 years in 2004, and it is expected to further
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increase in the near future (Bittles & Glasson, 2004; Glasson et al.,
2002). It is worth noting that such extension of the lifespan was of
greater amplitude than that occurring in the same years in the gen-
eral population, suggesting that the extremely short life expectancy
of DS persons in the past was not only due to the absence of effec-
tive medical treatments but also due to sociocultural factors. In fact,
the absence of biological knowledge and social repulsion pushed in
the past the medical community to consider the extremely short
life expectancy and poor health of these persons as inherent,
nonmodifiable traits of the syndrome. On the contrary, when these
persons are properly attended, not only does their life expectancy
increase spectacularly, but also the alterations at molecular and
cellular levels (e.g., immune alterations) result as less dramatic than
expected (Franceschi et al., 1978).
The increased life expectancy unfortunately is not paralleled by
an increased health span and DS face unhealthy aging characterized
by multimorbidity conditions, likely caused by the DS‐accelerated
aging phenotype. The progeroid aspects of DS were already postu-
lated by the pioneering work of George Martin in 1978. Today, an
indirect but eloquent clue supporting the idea that DS is character-
ized by an accelerated aging comes from routine clinical practice, as
DS persons move directly from pediatrics to geriatrics, skipping
almost completely the relatively long period of healthy adulthood
present in euploid persons.
At least three different layers of information support the view of
DS as a disorder of accelerated aging: (a) clinicopathological features;
(b) data showing high levels of markers of biological age in DS; and
(c) data showing an acceleration in DS of the molecular mechanisms
of aging. In the next sections, we will briefly summarize current
knowledge for each of these layers. Starting from this evidence, we
will discuss the possible strategies to hinder this accelerated aging,
especially for cognitive functions, with a special focus on metformin
as a candidate molecule.
2 | CLINICOPATHOLOGICAL FEATURES OF
ACCELERATED AGING IN DS
Accelerated aging in DS is evident in particular at the level of the
central nervous system, and by the age of about 50 years, most of
DS persons suffer from an early‐onset Alzheimer‐like dementia.
Actually, dementia is the second more frequent medical condition
after visual impairment present in adult DS persons (Capone et al.,
2018), and by far the most relevant health problem, as it entails a
loss of independence, a dramatic decrease in the quality of life, and
it represents a risk factor of mortality, together with mobility restric-
tions and epilepsy (Coppus et al., 2008). Typical neuropathological
hallmarks of Alzheimer’s disease (AD), including deposition of senile
plaques containing amyloid beta‐peptide (Aβ), chronic oxidative
stress, and neurofibrillary tangles composed of hyperphosphorylated
tau protein are already present by the age of 40 years in DS persons
(Lott, 2012). According to a recent study, the diagnosis of dementia
is posed on average at 55.8 years (SD ±6.29) and median survival
time after diagnosis is 3.78 years, with some differences between
males and females (Sinai et al., 2018). The gene for amyloid precur-
sor protein (APP) is triplicated in DS, being present in chromosome
21. Consequently, DS dementia is believed to be related to the over-
production of APP and consequent deposition of amyloid rather than
to a reduced clearance of Aβ, as it occurs in sporadic AD. Therefore,
DS dementia is considered more similar to familiar than sporadic
forms of AD (SAD). This tenet is also supported by consistent differ-
ences between DS and SAD including Aβ deposition patterns, char-
acterized by an increase in deposition of Aβ42 and diffused
subcortical plaques in DS (Fukuoka, Fujita, & Ito, 1990; Kida, Wis-
niewski, & Wisniewski, 1995), and neurological symptoms such as
seizures and incontinence, which tend to emerge earlier in DS (Zis &
Strydom, 2018). Finally, from a clinical point of view, DS persons
appear to be somewhat protected from cerebral amyloid angiopathy
and consequent risk of hemorrhage and stroke (Zis & Strydom,
2018). When comparing DS dementia with AD forms due to APP
gene microduplication, other differences in the clinical phenotype
have been reported (Zis & Strydom, 2018). Despite these important
differences between DS dementia and AD, typical signs of cognitive
decline and neuropsychological features of dementia (lowered scores
of battery tests for language and short memory skills, frontal lobe
functions, visuospatial abilities, and adaptive behavior) appear early
in DS persons (Arvio & Luostarinen, 2016; Ghezzo et al., 2014).
The immune system is also rapidly deteriorating in DS. It is
known that adult DS persons display a series of early‐onset changes
that apparently recapitulate in a shorter timescale the normal aging
process of the immune system, such as diminished NK cell activity,
decreased number of T and B lymphocytes, erosion of telomeres in
T lymphocytes, decreased response to mitogenic stimuli of blood
leukocytes, and increased risk of autoimmune disorders, among
others (Cuadrado & Barrena, 1996; Kusters, Verstegen, & Vries,
2011).
Many other age‐associated diseases display an early onset in DS
persons, including thyroid disorders (Prasher, 1999), osteopenia and
Key points
 Down syndrome is the most common genetic cause of
intellectual disability and appears to be characterized by
an accelerated aging, affecting in particular the central
nervous system, with a number of features that overlap
with Alzheimer’s disease.
 Social inclusion and cognitive training programs have
greatly improved DS cognitive performances over the
last decades; however, this advancement is largely frus-
trated by an early‐onset of an Alzheimer‐like dementia.
 No approved treatment exists so far to counteract such
peculiar cognitive condition. A number of clinical trials
have been performed but with unsatisfactory results.
Based on literature data, we propose that the use of
metformin could be worth investigating.
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osteoporosis (Carfì et al., 2017), overweight (Rubin, Rimmer, Chi-
coine, Braddock, & McGuire, 1998), visual and hearing impairment
(Kinnear et al., 2018), epidermal thickening (Kinnear et al., 2018),
cardiac atrophy, and moderate diastolic dysfunction (Vis et al., 2012).
In many cases, these pathologies occur simultaneously (Capone
et al., 2018; Kinnear et al., 2018). A possible exception to this rule is
the incidence of solid cancer. Actually, when testis and perhaps
other male genital cancers and stomach cancers are excluded, the
incidence of solid tumors in adult DS persons is markedly lower with
respect to age‐matched controls (Nižetić & Groet, 2012). This finding
is paradoxical if we consider that DS has many factors predisposing
to cancerogenesis, including chromosome instability, increased DNA
damage, and defective DNA repair systems, as well as the presence
on chromosome 21 of a number of oncogenes (Nižetić & Groet,
2012). This paradox likely reflects our lack of knowledge regarding
anti‐oncogenic mechanisms related to the trisomic condition and will
not be further discussed here.
3 | DS PERSONS ARE CHARACTERIZED BY
HIGH LEVELS OF MARKERS FOR
BIOLOGICAL AGE
A biomarker of age is defined as a biological parameter (or a combi-
nation of biological parameters) able to predict age‐related functional
decline and lifespan better than chronological age (Baker & Sprott,
1988; Butler et al., 2004; Johnson, 2006). Different potential
biomarkers of age have been proposed so far, and many of them
have been shown to grasp age‐acceleration effects (i.e., higher bio-
logical age), including cognitive decline and AD (Jylhävä, Pedersen, &
Hägg, 2017).
So far, four different biomarkers of age (namely telomere short-
ening, GlycoAgeTest, Horvath's epigenetic clock, and brain predicted
age) have been analyzed in DS persons. As described in the follow-
ing paragraphs, the results of these independent studies concor-
dantly point for an age‐acceleration effect in DS, indicating that DS
persons are biologically older than expected from their chronological
age.
Telomere attrition is a well‐established hallmark of aging. Despite
some conflicting results (Sanders & Newman, 2013), telomere short-
ening has been generally associated with age‐related physical/func-
tional decline and with mortality. It has been demonstrated that DS
persons have shorter telomeres than age‐matched controls (Vaziri
et al., 1993). Subsequent studies showed that telomere attrition is
associated with development of dementia in DS persons (Jenkins
et al., 2006, 2010), also in longitudinally assessed cohorts (Jenkins
et al., 2017), resembling the telomere shortening observed in AD
patients (Forero et al., 2016).
The GlycoAgeTest derives from the relative amounts of two
plasma N‐glycans, measured by means of a DNA sequencer‐aided,
fluorophore‐assisted carbohydrate electrophoresis (DSA‐FACE)
technique. This biomarker reliably increases with age after 40 years
(Dall'Olio et al., 2013; Vanhooren et al., 2009, 2007), and it is likely
to be indicative of the biological age of an individual, as patients
with Cockayne syndrome and with dementia were shown to have
higher GlycoAgeTest values than age‐matched healthy controls
(Vanhooren et al., 2010). We recently investigated N‐glycomic pro-
files in 76 DS persons of different ages, as compared with their
mothers and siblings (Borelli et al., 2015), and demonstrated that
GlycoAgeTest values resulted increased in DS persons as compared
to their siblings, in particular at young age. Moreover, GlycoAgeT-
est values were negatively correlated with Performances IQ score
(Borelli et al., 2015).
Epigenetic aging biomarkers, which rely on the widespread DNA
methylation changes occurring with age, have proven to be associ-
ated with a variety of age‐related conditions, including cognitive
decline and AD, and with mortality (Field et al., 2018; Horvath &
Raj, 2018). One of the most popular and widely used epigenetic
biomarkers of age, Horvath's epigenetic clock (Horvath, 2013), has
been applied to four independent sets of specimens from DS per-
sons, including whole blood, total peripheral blood leukocytes (PBL),
buccal epithelial cells, and brain postmortem biopsies. According to
this study, DS persons resulted as significantly older than their calen-
dar age, with an age acceleration ranging from 2.8 years in buccal
cells to 11.5 years in brain (Horvath et al., 2015).
Notably, the same trend of accelerated aging in DS brains has
been recently reported by using a totally different approach, that
is, magnetic resonance imaging (MRI; Cole et al., 2017). This aging
biomarker, based on a machine‐learning guided analysis of MRI
data (Cole et al., 2017), was previously associated with mild cogni-
tive impairment and AD (Franke & Gaser, 2012; Gaser, Franke,
Klöppel, Koutsouleris, & Sauer, 2013). By this method, Cole et al.
observed a brain predicted age difference (brain‐PAD) of 7.69 years
between adult DS persons (mean age 42.3 ± 8.7 years) and age‐
matched controls (Cole & Franke, 2017). Moreover, in DS persons
brain‐PAD correlated with evidence of beta‐amyloid deposition
(assessed with Positron Emission Tomography imaging) and with
cognitive impairment evaluated as CAMCOG score (Cole et al.,
2017).
Serum and urine metabolites can be useful biomarkers of age as
well. In a study on serum metabolomics, six serum metabolites were
identified as part of a putative signature of aging and measured also
in 53 DS persons (average age 28.3 years; Collino et al., 2013). Of
these six metabolites, 1‐O‐alkyl‐2‐acylglycerophosphocholine 32:0,
sphingomyelins 24:1 and 16:0 did not change in concentration as
compared to age‐matched controls, while tryptophan and lysophos-
phatidylcholines 18:2 and 20:4 had levels closely matching those of
elderly and centenarian subjects (Collino et al., 2013).
4 | MOLECULAR MECHANISMS OF AGING
ARE ALTERED IN DS PERSONS: THE SEVEN
PILLARS OF AGING
As discussed in the previous paragraph, different biomarkers of age
are concordantly altered in DS persons. Moreover, several observa-
tions suggest that the main molecular mechanisms involved in the
aging process are markedly altered in DS. These mechanisms, also
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referred as “the seven pillars of aging” (Kennedy et al., 2014), include
metabolism, stem cells and regeneration, macromolecular damage,
inflammation, adaptation to stress, proteostasis, and epigenetics. DS
persons display remarkable alterations for each of these “pillars,”
thus supporting the concept of DS as an accelerated aging syndrome
(Table 1). However, it is to note that in the majority of these studies,
the different pillars were not evaluated in cohorts of different ages,
or in longitudinal settings. Therefore, it is difficult to determine
whether the alterations observed in DS are inherent to the trisomy
rather than a sign of accelerated aging, or whether there is an inter-
action between the syndrome and the aging process. Further studies
are needed to specifically address this issue.
Taken together, these data support George Martin's pioneering
intuition that DS persons suffer from accelerated aging, affecting in
particular the nervous system. In the next paragraph, we will discuss
how this knowledge could be exploited in the search for new DS
therapeutic targets.
5 | HOW TO FACE THE COGNITIVE
DETERIORATION OF DS PERSONS?
Considering that DS persons become dependent on other people's
support at a relatively young age because of dementia, and that the
parents and families of DS persons also grow old and in some cases
cannot take care of them anymore, dementia in adult DS persons is
becoming not only an individual clinical problem but also a huge
family and public health emergency. It is now clear that integrated
interventions including social inclusion processes, schooling, and cog-
nitive training can be of great importance to improve cognitive capa-
bilities of DS persons. In particular, early programs of cognitive
training have been demonstrated to counteract effectively cognitive
deficits, by improving intellectual skills of DS persons (Connolly,
Morgan, Russell, & Fulliton, 1993; Couzens, Haynes, & Cuskelly,
2012).
No pharmacological intervention is at present approved for the
amelioration of cognitive deficits of DS (Dierssen, 2012; de la Torre
& Dierssen, 2012); however, a number of trials have been per-
formed by using drugs for AD, like acetylcholinesterase inhibitors
(donepezil, rivastigmine, galantamine), GABAergic antagonists (pen-
tetrazol), N‐methyl‐D‐aspartate receptor antagonists (memantine), or
microaliments (minerals, vitamins, antioxidants) that had little or no
success (Lott et al., 2011; de la Torre et al., 2016). More recently,
another promising molecule has been tested, that is, epigallocate-
chin gallate (EGCG), a natural polyphenol present in green tea
leaves. EGCG is a potent inhibitor of DYRK1A, one of the tripli-
cated genes believed to be involved in the brain alterations
observed in DS. EGCG has been tested in vitro and in clinical trials,
alone or in combination with cognitive training programs (de la
Torre et al., 2016, 2014). However, the beneficial effects of EGCG
appear largely inconsistent (Stagni et al., 2017; Stringer, Goodlett,
& Roper, 2017) and other studies are granted to confirm the effi-
cacy of this approach. Another possible pharmacological approach
is based on inhibitors of GABAA receptors or other modulators of
GABAA‐mediated transmission, such as NKCC1 (Contestabile,
Magara, & Cancedda, 2017). In fact, studies on DS animal models
have demonstrated that GABAA antagonists such as pentylenetetra-
zole (PTZ) are able to improve many cognitive functions of the
Ts65Dn mice (novel object recognition, Morris water maze test;
Braudeau et al., 2011; Martínez‐Cué et al., 2013), while NKCC1
inhibitors such as bumetanide can improve discriminative memory,
spatial and associative memory (Deidda et al., 2015). On these pre-
mises, a number of clinical trials have been performed with this
kind of drugs. Some of them are still ongoing, and the results are
eagerly awaited, while others (NCT02024789 and NCT02484703)
showed a good tolerance but a lack of global efficacy (Contestabile
et al., 2017).
Despite these somehow disappointing results, the strategy of
combining together cognitive training and pharmacological therapies
is appealing and certainly deserves attention. However, it is emerg-
ing that the rationale used so far (i.e., targeting presumed AD molec-
ular pathways) is not effective, and an alternative approach should
be urgently pursued.
TABLE 1 Alterations of the aging molecular mechanisms (pillars) in DS
Aging pillars DS phenotype
Metabolism  ↑ mTOR pathway activation (Di Domenico et al., 2018) ↑ oxidative stress (Garlet et al.., 2013; Valenti, Manente, Moro, Marra, & Vacca, 2011) ↑ mitochondrial dysfunction (Conte et al., 2018; Helguera et al., 2013) widespread age‐related deregulation of red blood cell metabolism (Culp‐Hill et al., 2013)
Stem cells and regeneration  ↓ self‐renewal of stem cells (Adorno et al., 2013; Cairney et al., 2009)
Macromolecular damage  ↑ oxidative damage (Cenini et al., 2012; Franceschi et al., 1992) ↑ sensitivity to DNA damaging agents (Morawiec et al., 2008)
Inflammation  ↑ chronic inflammation (Zhang et al., 2017) ↑ accumulation of immune cells with memory phenotype (Cossarizza et al., 1990, 1991)
Adaptation to stress  ↑ difficulties to cope with increased proteomic stressors (Aivazidis et al., 2017)
Proteostasis  ↓ proteostasis (Aivazidis et al., 2017; Di Domenico et al., 2013)
Epigenetics  Age‐related changes in epigenetic machinery (Ciccarone et al., 2018) ↑ DNA methylation age (Horvath et al., 2015)
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We propose that the new vision of Geroscience could be imple-
mented in DS management. According to this approach, aging and
age‐related diseases share the same common molecular mechanisms
(the seven aging pillars mentioned above), and thus, tackling these
mechanisms should in principle counteract both aging and age‐re-
lated diseases at a time (Franceschi et al., 2018; Kennedy et al.,
2014). Considering that DS persons are likely suffering from an
accelerated aging that in turn impinges on the same pillars that are
at the basis of physiological aging, as we have discussed thus far, it
can be predicted that DS could effectively benefit from the emerging
anti‐aging approaches. In this regard, a number of strategies able to
impact on the molecular mechanisms involved in the aging process
are currently under investigation, including dietary interventions
mimicking chronic dietary restriction, drugs that inhibit the growth
hormone/IGF‐I axis or the mTOR‐S6K pathway, drugs that activate
AMPK or specific sirtuins, and anti‐inflammatory drugs (Longo et al.,
2015), some of them being already in clinical trial.
A detailed description of the experimental evidence supporting
these strategies has been provided elsewhere (Longo et al., 2015);
however, that some of these interventions, in particular regimens
of dietary restriction, have been proven to be protective against
neurodegenerative pathologies in experimental models. In particu-
lar, periodic protein restriction cycles have been shown to promote
changes in circulating growth factors and tau phosphorylation asso-
ciated with protection against age‐related neuropathologies in mice
(Parrella et al., 2013). Similarly, calorie restriction has been
reported to reduce significantly hippocampal Aβ burden and
expression of components of the γ‐secretase complex in female
mice of the Tg2576 experimental model of cerebral amyloidosis
(Schafer et al., 2015). Finally, many dietary interventions have been
shown to ameliorate various cognitive and behavioral tests in rat
models of aging and neurodegeneration (Wahl et al., 2017).
Accordingly, clinical trials have been performed or are currently
ongoing to evaluate the efficacy of such regimens on humans
(Horie et al., 2016; Tussing‐Humphreys et al., 2017). However, it
can be difficult to obtain sufficient adherence to such dietary pro-
tocols in DS persons; therefore, alternative approaches are desir-
able, including intermittent fasting or calorie restriction mimetics. A
prototypical calorie restriction mimetic is rapamycin, a macrolide
compound widely used as an immunosuppressant drug. Rapamycin
has been demonstrated to extend lifespan in a number of animal
models by inhibiting mTOR/S6 pathway. Numerous studies have
demonstrated a deregulation of mTOR pathway in DS (Bacalini
et al., 2015; Perluigi & Butterfield, 2012) and have linked the alter-
ations of mTOR pathway to cognitive decline, AD, and AD‐like
dementia in DS (Di Domenico et al., 2018). There is thus rationale
for the use of rapamycin or other rapalogues in conditions where
mTOR is altered, including also autistic spectrum disorders and epi-
lepsy (Bockaert & Marin, 2015). However, it has to be considered
that rapamycin has important side effects, which can limit its off‐
label use as an anti‐aging drug. These include, among others, meta-
bolic dysregulation (e.g., hyperglycemia, hyperinsulinemia, and insu-
lin resistance) and proliferative defects in hematopoietic lineages
(Soefje, Karnad, & Brenner, 2011), which could be particularly sev-
ere in DS persons.
Another strategy that appears particularly promising is the use of
drugs able to selectively kill senescent cells in vivo. Treatments with
these “senolytic” drugs are capable of exerting beneficial effects on
old animals and delay or block the onset and progression of age‐re-
lated diseases (Jeon et al., 2017; Takata et al., 2013). Such an
approach could be of great interest for DS persons. A specific inves-
tigation on the occurrence of cell senescence in adult DS persons
has not yet been conducted; however, it is known that signs of cell
senescence are observed in amniocytes and trophoblasts from pla-
centas and embryos with trisomy 21 (Amiel et al., 2013; Biron‐Shen-
tal, Liberman, Sharvit, Sukenik‐Halevy, & Amiel, 2015). Moreover,
fibroblasts from DS fetuses undergo cell senescence more frequently
than fibroblasts from classically developing fetuses, as assessed by
senescence‐associated beta‐Gal and p21 expression (Rodríguez‐Sur-
eda, Vilches, Sánchez, Audí, & Domínguez, 2015). However, the
strategy with senolytic drugs, though promising, is not yet an option
as these drugs are still under preclinical investigation.
Finally, it has been reported that lithium, a drug approved for
human use as mood stabilizer, can extend lifespan in animal models
through the inhibition of GSK‐3 and activation of NRF2 (Castillo‐
Quan et al., 2016); therefore, it could be considered an additional
approach to delay the aging process. Interestingly, a number of stud-
ies have examined the effects of chronic lithium administration on
adult neurogenesis in the Ts65Dn mouse model of DS (Bianchi,
Ciani, Contestabile, Guidi, & Bartesaghi, 2010; Contestabile et al.,
2013; Faundez et al., 2018; Guidi et al., 2017). These studies indi-
cated that the administration of lithium can restore the neurogenesis
in adulthood thus rescuing the synaptic plasticity of newborn neu-
rons, that in turn leads to the recovery of behavioral performance in
fear conditioning, object location, and novel object recognition tests
(Contestabile et al., 2013), as well as olfactory functions (Guidi et al.,
2017). Studies on human cells are lacking; however, we reported
years ago that lithium chloride was able to increase the proliferative
capability of PBMC from DS subjects after a sub‐optimal stimulation
with mitogenic lectins (Licastro et al., 1983). These studies suggest
that lithium‐based therapies should be further explored as a potential
strategy to counteract cognitive decline of DS persons. At present,
we are not aware of human studies or clinical trials with lithium‐
based drugs on DS persons, and the numerous possible side effects
(including tremors, nausea, vomiting, and feelings of unease) and
contraindications (including thyroid disorders, which are very fre-
quent in DS) may discourage this type of approach for DS persons.
6 | IS METFORMIN A POSSIBLE
CANDIDATE FOR COMBATING DS
COGNITIVE DECLINE?
Among the molecules that can be considered for their possible anti‐
aging effects, there is metformin, a long‐time known biguanide (1,1‐
dimethylbiguanide hydrochloride) largely used for Type 2 Diabetes
(T2D). Metformin is able to activate AMPK (Takata et al., 2013), a
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kinase crucial for the regulation of lipid metabolism, cellular glucose
uptake, and mitochondria biogenesis, which is believed to mediate
the majority of metformin effects on insulin resistance and metabo-
lism. Beside these effects, metformin has also senomorphic activities,
that is, the capability to inhibit cell senescence and its related delete-
rious secretory phenotype (Moiseeva et al., 2013; Noren Hooten
et al., 2016). Accordingly, metformin increases lifespan on animal
models such as mice (Anisimov et al., 2005, 2011) and Caenorhabdi-
tis elegans (Cabreiro et al., 2013). A number of data have shown that
metformin offers a protection against AD, likely through different
mechanisms, including the inhibition of Aβ fibril deposition (Markow-
icz‐Piasecka et al., 2017), a protein phosphatase 2‐mediated reduc-
tion of tau phosphorylation (Kickstein et al., 2010), and a promotion
of neurogenesis through the activation of an atypical PKC‐CBP path-
way (Wang et al., 2012). Moreover, it is known that AMPK can regu-
late mTOR, the main inhibitor of autophagy (Ravikumar et al., 2010).
Therefore, metformin acts as an anti‐aging drug also by activating
autophagy, a process that seems to be deranged in neurodegenera-
tive disorders (Boland et al., 2008; Cataldo, Hamilton, Barnett,
Paskevich, & Nixon, 1996). Treatment with metformin is associated
with a 51% reduced risk of cognitive impairment (defined by modi-
fied Mini‐Mental Status Exam score ≤23) (Ng et al., 2014) and low-
ers the risk of dementia in T2D patients as compared with other
diabetes medications (Cheng et al., 2014; Orkaby, Cho, Cormack,
Gagnon, & Driver, 2017). Another study examining the effect of dia-
betes treatment on specific cognitive domains (verbal learning, work-
ing memory, and executive functions) over 4 years showed that only
participants who used metformin alone had better cognitive function
compared to participants who used other anti‐diabetic drugs (Herath,
Cherbuin, & Eramudugolla, 2016). A recent meta‐analysis that con-
sidered these and other studies concluded that cognitive impairment
is significantly less prevalent in diabetic patients treated with met-
formin (odds ratio = 0.55, 95% CI 0.38–0.78), and dementia inci-
dence is also significantly reduced (hazard ratio = 0.76, 95% CI 0.39–
0.88; Campbell et al., 2018). As a whole, these studies clearly sug-
gest that metformin can effectively counteract neuronal progressive
degeneration and dementia; furthermore, it appears that metformin
can offer protection also toward other age‐related diseases such as
cardiovascular diseases and some types of cancer; therefore, life
expectancy of metformin‐treated T2D patients can be higher than
age‐matched nondiabetic controls (Amin, Lux, & O'Callaghan, 2018;
Bannister et al., 2014; Barzilai, Crandall, Kritchevsky, & Espeland,
2016; Vancura, Bu, Bhagwat, Zeng, & Vancurova, 2018). For these
reasons, metformin is going to be tested in the TAME trial on elderly
persons with the final goal to evaluate its effects on cardiovascular
events, cancer, dementia, and mortality (Barzilai et al., 2016).
In the same vein, and considering its safety profile, metformin
could be a promising candidate for possible clinical trials also on DS
persons. Preliminary data on the effectiveness of metformin on DS
come from a recent in vitro study, where it has been demonstrated
that metformin can restore mitochondrial alterations in DS fetal
fibroblasts, by inducing the transcriptional coactivator PGC‐1α
responsible for mitochondrial biogenesis (Izzo et al., 2017).
DS persons could also benefit from anti‐inflammatory properties
of metformin, due to its effects on N‐glycan biomarkers (de Kreutzen-
berg et al., 2015), on metabolic parameters such as hyperglycemia,
insulin resistance, and atherogenic dyslipidemia, but also on the inhibi-
tion of NF‐κB activation, ROS, and advanced glycation end‐products
(AGEs) formation (Saisho, 2015). Indeed, it has been reported that DS
brain displays signs of neuroinflammation (Wilcock et al., 2015), and
that DS persons are characterized by chronically elevated levels of
some inflammatory markers such as IL‐1β, IL‐6, and TNF‐α since
young age (Iulita et al., 2016). Such markers are elevated also in AD
patients and correlate with low brain functions. In particular, IL‐6 and
C‐reactive protein resulted associated with a decline over time of
cerebral function, assessed as blood flow with PET, in regions impor-
tant for cognition such as the orbitofrontal cortex and hippocampus
(Warren et al., 2018). Another astrocyte cytokine, S100B, is elevated
in both DS and AD, and it has been reported to induce the synthesis
of APP, which can activate microglia that in turn produces IL‐1β (Bar-
ger & Harmon, 1997; Li et al., 1998). Thus, excess levels of neural IL‐
1β and S100B can influence the neuropathogenesis of AD in DS
(Mrak & Griffin, 2004). The progressive, age‐related increase in circu-
lating pro‐inflammatory mediators has been conceptualized as inflam-
maging, and it fuels/triggers many age‐related diseases (Franceschi
et al., 2000; Franceschi & Campisi, 2014). It is therefore conceivable
that DS persons are characterized by a peculiar form of inflammaging
and that the AD‐like dementia occurring in adult DS persons is at
least in part sustained by inflammatory cytokines leading to the pro-
duction and maturation of amyloid plaques.
Finally, it is known that hypothyroidism is one of the most frequent
conditions present in adult DS persons, and to this regard, metformin
has been reported to decrease the levels of TSH in hypothyroid
patients, thus offering a potential protection against enlargement of thy-
roid gland, goiter, and nodules (Meng, Xu, Chen, Derwahl, & Liu, 2017).
7 | CONCLUSIONS
Past attempts to face cognitive decline and dementia in DS persons
have largely failed. We think it is time for a change in strategy, and,
while waiting for specific targets of the AD‐like dementia, we should
try to tackle accelerated aging, under the assumption that this
approach will also combat related ailments such as dementia. This
strategy should possibly include, other than lifestyle and personalized
approaches, also dietary interventions and drugs that have proven
effective in (or at least good candidate for) delaying/combating the
aging process. We have briefly discussed experimental evidence that
in particular metformin could be a candidate molecule. In fact, at vari-
ance with past approaches, metformin has proven to be effective in
preventing a number of phenomena related to both AD dementia and
aging at a time. This does not exclude other molecules and therapeu-
tic approaches, and our aim with the present paper was to stimulate
an international debate on this topic, in order to obtain a broad con-
sensus finalized to promote appropriately designed rigorous trials, cap-
able of taking into account the clinical heterogeneity of DS persons,
particularly when they grow old (Lott, 2012). This scientific debate is
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also of critical urgency to protect DS persons and their families from
a “do‐it‐yourself” approach to this new generation of anti‐aging treat-
ments as well as from underpowered investigations. This debate
should involve not only the scientific community, but also families,
caregivers, and patient's associations. Owing to the clinical complexity
and social implications of DS, we strongly encourage the participation
of experts in different fields (pediatricians, neurologists, pharmacolo-
gists, biogerontologists, geriatricians, geneticists, and psychiatrists,
among others). Considering the complex ethical and clinical issues/
caveats related to such trials, pilot proof of principle studies with ade-
quate power should provide guidelines for more extended studies
regarding the type of intervention, the age at which it should start,
schedule, doses, etc. We are aware that this topic is a delicate issue
and that there are open questions still unanswered regarding not only
the efficacy of this possible treatment, but also its side effects, perma-
nence after discontinuation, and the cognitive functions that can be
actually modified/preserved. Finally, last but not least, we think that
the opening of such an international debate would be an opportunity
for the scientific community to start discussing the possibility of
extending this type of strategy to other types of patients including
elderly people with early signs of cognitive impairment.
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